Amgen downgraded to "neutral"

11.05.07 - HSBC

NEW YORK, May 11 (newratings.com) - Analysts at HSBC downgrade Amgen Inc (AMGN) from "overweight" to "neutral." The target price has been reduced from $87 to $65.